investigated the effects of monoclonal antibodies against IL-1α and IL-1β in atherosclerosis in vivo which demonstrated that IL-1β has a profound effect on late-stage atherosclerosis by increasing IL-10 in the plasma. Here, IL1A is linked to atherosclerosis.